VMT-⍺-NET — Interim data
2026
Phase 1/2 Data Expected Across All 3 Clinical Programs in 2026Source filing
CATX biotech catalysts & pipeline
PERSPECTIVE THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
[ 212 Pb]PSV359 — Topline data
By late 2026
By late 2026, these patients will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to have completed at least one scan after the full course of treatment (up to four doses every eight weeks).Source filing
[ 212 Pb]VMT-α-NET — Topline data
By late 2026
By late 2026, all 46 patients in Cohort 2 will have had the opportunity for at least 60 weeks of follow-up since beginning treatment.Source filing
[212Pb]PSV359 — Topline data
Late 2026
Clinical updates expected in mid to late 2026 for VMT01 targeting melanoma and PSV359 targeting FAP across multiple solid tumors, as well as potential additions to the clinical pipeline to be guided by first-in-human imagesSource filing
lapemelanotide zapixetar (VMT01) — Topline data
By late 2026
By late 2026, the 10 patients who had received VMT01 3.0 mCi treatment since the initiation or re-opening of these cohorts in September 2025 will have had the opportunity for at least 24 weeks of follow-up after their initial doses, sufficient time to have completed at least one scan after the full course of treatment (up to three doses every eight weeks).Source filing
[212Pb]PSV359 — Initial data
in 2027
The next clinical update is planned in 2027.Source filing
bamzireotide navoxetan (VMT-α-NET) — Conference presentation
Oct 23
Updated data on NETs patients will be presented at ESMO on October 23.Source filing